SEARCH

SEARCH BY CITATION

References

  • 1
    Brillanti S, Garson J, Foli M,et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.Gastroenterology1994; 107: 812 817
  • 2
    Brouwer JT, Nevens F, Michielsen P,et al. What options are left when hepatitis C does not respond to interferon? Placebo-controlled Benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferon (abstract WP2/08).J Hepatol1994; 21 Suppl 1: S17
  • 3
    Chemello L, Cavaletto L, Bernardinell E,et al. Response to ribavirin, to interferon and to a combination of both in patients with chronic hepatitis C and its relation to HCV genotypes (abstract GS 5/29).J Hepatol1994; 21 Suppl 1: S12
  • 4
    Reichard O, Norkrans G, Fryden A,et al. Randomized double-blind placebo-controlled study of Interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet1998; 351: 83 87
  • 5
    Israel BC, Blouin RA, McIntyre W, Shedlofsky SIEffects of interferon-α on hepatic drug metabolism in cancer patients.Br J Clin Pharmacol1993; 36: 229 235
  • 6
    Garrattini SPerspectives in the field of drug metabolism.Drug Metab Rev1994; 26: 537 573
  • 7
    Laskin OL, Longstreth JA, Hart CA,et al. Ribavirin disposition in high risk patients for acquired immunodeficiency syndrome.Clin Pharmacol Ther1987; 41: 546 555
  • 8
    Lertora JJL, Rege AB, Lacour JT,et al. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus.Clin Pharmacol Ther1991; 50: 442 449
  • 9
    Gibaldi M & Perrier DPharmacokinetics, 2nd ed. New York, Marcel Dekker, 1982, 409 417
  • 10
    Di Bisceglie AM, Conjeevaram HS, Fried MW,et al. Ribavirin as therapy for chronic hepatitis C.Ann Int Med1995; 123: 897 903
  • 11
    Catlin DH, Smith RA, Samuels AI14C-Ribavirin distribution and pharmacokinetic studies in rats, baboons and man. In Ribavirin: A broad spectrum antiviral agent, eds Smith RA, Kirkpatrick W, New York, Academic Press, 1980, pp 83 98
  • 12
    Ferrara EA, Oishi JS, Wannemacher RW Jr,et al. Plasma dissapearance, urine excretion and tissue distribution of ribavirin in rats and rhesus monkeys.Antimicrob Agents Chemother1981; 19: 1042 1049
  • 13
    Steinijans VW, Hartmann M, Huber R,et al. Lack of pharmacokinetic interaction as a bioequivalence problem.Int J Clin Pharmacol Toxicol1991; 29: 323 328
  • 14
    Piscitelli SC, Amantea MA, Vogel S,et al. Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines.Antimicrob Agents Chemother1996; 40: 161 165
  • 15
    Paroni R, Del Puppo M, Borghi C,et al. Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers.Int J Clin Pharmacol Ther Toxicol1989; 27: 302 307
  • 16
    Jarvis SM, Thorn JA, Glue PRibavirin uptake by human erythrocytes is mediated by es nucleoside transporters.Br J Pharmacol1998; (in press).
  • 17
    Griffith, DA DA, Jarvis Jarvis, SM SMNucleoside and nucleobase transport systems of mammalian cells.Biochim Biophys Acta,1996; 1286: 153 181
  • 18
    Griffiths M, Beaumont N, Yao SYM,et al. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs.Nature Medicine,1997; 3, 89 93
  • 19
    Nakajima S, Kuroki T, Shintani M,et al. Changes in interferon receptors on peripheral blood lymphocytes in patients with chronic hepatitis B being treated with interferon.Hepatology1990; 12: 1261 1265
  • 20
    Pestka S, Langer JA, Zoon KC, Samuel CEInterferons and their actions.Ann Rev Biochem1987; 56: 727 777
  • 21
    Fuchs D, Weiss G, Reibnegger G, Wachter HThe role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases.Crit Rev Clin Lab Sci1992; 29: 307 341
  • 22
    Witt PL, Storer BE, Bryan GT,et al. Pharmacodynamics of biological response in vivo after single and multiple doses of Interferon-β. J Immunother1993; 13: 191 200
  • 23
    Musolino C, Grosso P, Alonci A,et al. Serum levels of 2′5′ oligoadenylate synthetase during interferon therapy in patients with B-cell chronic lymphocytic leukemia.Am J Hematol1993; 43: 1 4
  • 24
    Glue P, Cutler D, Sabo R,et al. Pharmacodynamic effects of interferon alfa-2b in healthy volunteers.Clin Pharmacol Ther1996; 59: 205 (abstract).